News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week In Review: Chi-Next Exchange Rejects BGI's $260 Million IPO Application



11/7/2016 9:01:55 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
The Chi-Next Exchange rejected a $260 million IPO from BGI, Shenzhen's giant genomics sequencing company, because of insufficient documentation; TaiGen Biotech formed a $102 million Taiwan-China JV with YiChang HEC Pharma to develop a dual-drug antiviral hepatitis C treatment; Decheng Capital led a $12 million Series A investment in Cirina, a San Francisco diagnostics maker; DiaCarta, a San Francisco-Nanjing diagnostics company, received a $300,000 grant to validate its RadTox QuantiDNATM product to assess cancer radiation response; Medbanks, a Beijing oncology big data company, announced a strategic partnership with IMS Health; Fosun Pharma acquired China rights to an anti-MET monoclonal antibody developed by US-based Kolltan Pharma; Xbrane Biopharma of Sweden signed a $7.6 million term sheet with an unnamed China pharma for China distribution of a long-acting cancer drug; Merck of Germany officially opened its new $189 million Nantong drug plant and announced another $89 million investment in a nearby Life Science center; Pfizer received CFDA approval to market Prevenar 13®, a pneumococcal vaccine intended for infants; Suzhou Alphamab will start a China Phase I trial of a biologic treatment for infertility; and the CFDA will begin accepting priority review applications for medical devices in January 2017.

Read at ChinaBio Today


comments powered by Disqus
BGI
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES